Literature DB >> 18395970

Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors.

Fulvio Chiacchiera1, Cristiano Simone.   

Abstract

In the last year, several evidences indicated that pharmacological manipulation of relevant signaling pathways could selectively affect gene expression to influence cell fate. These findings render of extreme importance the elucidation of how external stimuli are transduced to mediate chromatin modifications, resulting in a permissive or repressive environment for gene expression. These signaling cascades activate or repress the function of chromatin binding proteins that represent attractive pharmacological targets for human diseases. Actually, the closer the target is to chromatin, the more the transcriptional effect will be selective. Recent studies suggest that pharmacological manipulation of signaling pathways to modulate cell fate is indeed possible and that chromatin-associated kinases could represent an optimal target. The p38 MAPK is the prototype of this class of enzymes and its central role in the transcription process is evolutionary conserved. In this review we will focus on the possibility to inhibit p38alpha in colorectal cancer to arrest tumor progression and induce autophagic cell death.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395970     DOI: 10.1016/j.canlet.2008.02.061

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy.

Authors:  Salome Paillas; Annick Causse; Laetitia Marzi; Philippe de Medina; Marc Poirot; Vincent Denis; Nadia Vezzio-Vie; Lucile Espert; Hayat Arzouk; Arnaud Coquelle; Pierre Martineau; Maguy Del Rio; Sophie Pattingre; Céline Gongora
Journal:  Autophagy       Date:  2012-05-31       Impact factor: 16.016

Review 2.  p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.

Authors:  Valentina Grossi; Alessia Peserico; Tugsan Tezil; Cristiano Simone
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.

Authors:  Salomé Paillas; Florence Boissière; Fréderic Bibeau; Amélie Denouel; Caroline Mollevi; Annick Causse; Vincent Denis; Nadia Vezzio-Vié; Laetitia Marzi; Cédric Cortijo; Imade Ait-Arsa; Nadav Askari; Philippe Pourquier; Pierre Martineau; Maguy Del Rio; Céline Gongora
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

4.  Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signalling.

Authors:  G Chatzinikolaou; D Nikitovic; A Berdiaki; A Zafiropoulos; P Katonis; N K Karamanos; G N Tzanakakis
Journal:  Cell Prolif       Date:  2009-10-21       Impact factor: 6.831

5.  Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response.

Authors:  Valentina Grossi; Micaela Liuzzi; Stefania Murzilli; Nicola Martelli; Anna Napoli; Giuseppe Ingravallo; Alberto Del Rio; Cristiano Simone
Journal:  Cancer Biol Ther       Date:  2012-09-17       Impact factor: 4.742

6.  Ataxia-telangiectasia mutated (ATM) participates in the regulation of ionizing radiation-induced cell death via MAPK14 in lung cancer H1299 cells.

Authors:  Nan Liang; Rui Zhong; Xue Hou; Gang Zhao; Shumei Ma; Guanghui Cheng; Xiaodong Liu
Journal:  Cell Prolif       Date:  2015-08-13       Impact factor: 6.831

7.  Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase.

Authors:  Valentina Grossi; Cristiano Simone
Journal:  J Oncol       Date:  2012-03-11       Impact factor: 4.375

8.  Frequent activation of EGFR in advanced chordomas.

Authors:  Barbara Dewaele; Francesca Maggiani; Giuseppe Floris; Michele Ampe; Vanessa Vanspauwen; Agnieszka Wozniak; Maria Debiec-Rychter; Raf Sciot
Journal:  Clin Sarcoma Res       Date:  2011-07-25

9.  P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.

Authors:  Gabriel G Vega; Alejandro Avilés-Salas; J Ramón Chalapud; Melisa Martinez-Paniagua; Rosana Pelayo; Héctor Mayani; Rogelio Hernandez-Pando; Otoniel Martinez-Maza; Sara Huerta-Yepez; Benjamin Bonavida; Mario I Vega
Journal:  BMC Cancer       Date:  2015-10-16       Impact factor: 4.430

10.  Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications.

Authors:  S Baldari; V Ubertini; A Garufi; G D'Orazi; G Bossi
Journal:  Cell Death Dis       Date:  2015-01-29       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.